Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

Rottapharm S.p.A., Xytis Pharmaceuticals deal

January 17, 2005 8:00 AM UTC

Xytis received exclusive development and marketing rights to Rottapharm's neboglamine ( CR2249) to treat schizophrenia and other CNS disorders. Xytis' rights include the U.S., Canada, Japan, Australi...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article